Patents by Inventor Yong Wha Moon

Yong Wha Moon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230365932
    Abstract: Provided are a composition for culturing NK cells, and a method of culturing NK cells using the same. According to an aspect, in culturing NK cells from peripheral blood mononuclear cells, when NK cells are cultured in a medium including the composition for culturing NK cells, the composition including IL-15, IL-18, and IL-27, the NK cells may proliferate in large quantities and activation of NK cells may be promoted. Therefore, when the NK cells are used, cancer cell apoptosis or cancer cell-killing ability may be promoted. Accordingly, the NK cells may be used as an effective adoptive immune cell therapy product in cancer prevention or treatment.
    Type: Application
    Filed: July 17, 2023
    Publication date: November 16, 2023
    Applicant: SUNGKWANG MEDICAL FOUNDATION
    Inventors: Hee Jung AN, Yeon Ho CHOI, Eun Jin LIM, Yong Wha MOON, Se Wha KIM
  • Patent number: 11746327
    Abstract: Provided are a composition for culturing NK cells, and a method of culturing NK cells using the same. According to an aspect, in culturing NK cells from peripheral blood mononuclear cells, when NK cells are cultured in a medium including the composition for culturing NK cells, the composition including IL-15, IL-18, and IL-27, the NK cells may proliferate in large quantities and activation of NK cells may be promoted. Therefore, when the NK cells are used, cancer cell apoptosis or cancer cell-killing ability may be promoted. Accordingly, the NK cells may be used as an effective adoptive immune cell therapy product in cancer prevention or treatment.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: September 5, 2023
    Assignee: SUNGKWANG MEDICAL FOUNDATION
    Inventors: Hee Jung An, Yeon Ho Choi, Eun Jin Lim, Yong Wha Moon, Se Wha Kim
  • Publication number: 20230257710
    Abstract: A method of culturing high-purity, highly active natural killer cells of which expression of anti-cancer-related gene is regulated, and use thereof for anticancer immunotherapy are provided. In the natural killer cells, the expression of anticancer related genes is significantly increased or decreased before and after culture. The natural killer cells have the unique characteristics thereof, and remarkably high activity and proliferation fold. Therefore, the natural killer cells can be used for effective anticancer immunotherapy.
    Type: Application
    Filed: April 14, 2023
    Publication date: August 17, 2023
    Inventors: Young Seok BAEK, Hee Jung AN, Myung Seo KANG, Yong Wha MOON, Kyung Soon PARK, In Jee LEE, So Hyun HWANG
  • Publication number: 20210095249
    Abstract: Provided are a composition for culturing NK cells, and a method of culturing NK cells using the same. According to an aspect, in culturing NK cells from peripheral blood mononuclear cells, when NK cells are cultured in a medium including the composition for culturing NK cells, the composition including IL-15, IL-18, and IL-27, the NK cells may proliferate in large quantities and activation of NK cells may be promoted. Therefore, when the NK cells are used, cancer cell apoptosis or cancer cell-killing ability may be promoted. Accordingly, the NK cells may be used as an effective adoptive immune cell therapy product in cancer prevention or treatment.
    Type: Application
    Filed: November 20, 2018
    Publication date: April 1, 2021
    Applicant: SUNGKWANG MEDICAL FOUNDATION
    Inventors: Hee Jung AN, Yeon Ho CHOI, Eun Jin LIM, Yong Wha MOON, Se Wha KIM
  • Patent number: 9422298
    Abstract: The invention provides novel substituted pyridopyrimidines represented by Formula I or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof, and a composition comprising these compounds. The compounds provided can be used as inhibitors of the phosphoinositide 3? OH kinase family (PI3K) for the treatment of inflammatory diseases, cancer, cardiovascular diseases, allergy, asthma and autoimmune disorders.
    Type: Grant
    Filed: February 13, 2015
    Date of Patent: August 23, 2016
    Assignees: CMG Pharmaceutical Co., Ltd., Sung Kwang Medical Foundation
    Inventors: Gilnam Lee, Chul Soo Lim, Han Won Cho, Jeongbeob Seo, Albert C. Gyorkos, Suk Young Cho, Eun Kyung Choi, Choung Soo Kim, Jung Jin Hwang, Jin Sung Kim, Hee Jung An, Yong Wha Moon